E-resources
-
Christensen, Emil; Birkenkamp-Demtröder, Karin; Sethi, Himanshu; Shchegrova, Svetlana; Salari, Raheleh; Nordentoft, Iver; Wu, Hsin-Ta; Knudsen, Michael; Lamy, Philippe; Lindskrog, Sia Viborg; Taber, Ann; Balcioglu, Mustafa; Vang, Søren; Assaf, Zoe; Sharma, Shruti; Tin, Antony S; Srinivasan, Ramya; Hafez, Dina; Reinert, Thomas; Navarro, Samantha; Olson, Alexander; Ram, Rosalyn; Dashner, Scott; Rabinowitz, Matthew; Billings, Paul; Sigurjonsson, Styrmir; Andersen, Claus Lindbjerg; Swenerton, Ryan; Aleshin, Alexey; Zimmermann, Bernhard; Agerbæk, Mads; Lin, Cheng-Ho Jimmy; Jensen, Jørgen Bjerggaard; Dyrskjøt, Lars
Journal of clinical oncology, 06/2019, Volume: 37, Issue: 18Journal Article
Novel sensitive methods for early detection of relapse and for monitoring therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome for patients with bladder cancer. We addressed the prognostic and predictive impact of ultra-deep sequencing of cell-free DNA in patients before and after cystectomy and during chemotherapy. We included 68 patients with localized advanced bladder cancer. Patient-specific somatic mutations, identified by whole-exome sequencing, were used to assess circulating tumor DNA (ctDNA) by ultra-deep sequencing (median, 105,000×) of plasma DNA. Plasma samples (n = 656) were procured at diagnosis, during chemotherapy, before cystectomy, and during surveillance. Expression profiling was performed for tumor subtype and immune signature analyses. Presence of ctDNA was highly prognostic at diagnosis before chemotherapy (hazard ratio, 29.1; = .001). After cystectomy, ctDNA analysis correctly identified all patients with metastatic relapse during disease monitoring (100% sensitivity, 98% specificity). A median lead time over radiographic imaging of 96 days was observed. In addition, for high-risk patients (ctDNA positive before or during treatment), the dynamics of ctDNA during chemotherapy was associated with disease recurrence ( = .023), whereas pathologic downstaging was not. Analysis of tumor-centric biomarkers showed that mutational processes (signature 5) were associated with pathologic downstaging ( = .024); however, no significant correlation for tumor subtypes, DNA damage response mutations, and other biomarkers was observed. Our results suggest that ctDNA analysis is better associated with treatment efficacy compared with other available methods. ctDNA assessment for early risk stratification, therapy monitoring, and early relapse detection in bladder cancer is feasible and provides a basis for clinical studies that evaluate early therapeutic interventions.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.